FlashBot Vascular Interventional Surgery Robot

FlashBot is RainMed Medical’s platform-level vascular interventional surgical robot designed to cover the complete diagnosis-to-treatment workflow in coronary and peripheral vascular interventions. The system integrates the company’s proprietary caFFR and caIMR diagnostic modules with robotic catheter manipulation capabilities.

Product Overview

Positioned as China’s first vascular interventional robot covering the entire diagnostic and treatment process, FlashBot aims to address several challenges in interventional cardiology: radiation exposure to operators, procedural consistency, and access to specialist expertise in underserved regions.

The system architecture combines three functional components that serve as the robot’s “eye,” “brain,” and “hand” to assist operators throughout interventional procedures.

System Architecture

Surgical Image Navigation System (“Eye”)

The navigation system integrates multi-modal medical images for accurate procedural guidance. Real-time imaging fusion enables precise catheter positioning and lesion targeting.

Console System (“Brain”)

The console integrates RainMed’s diagnostic algorithms including:

• caFFR module: Provides coronary stenosis functional assessment
• caIMR module: Evaluates microcirculation status
• Surgical planning: AI-assisted treatment strategy recommendations

This integration enables the robot to “observe” lesion characteristics and “think” about optimal treatment approaches.

Bedside Manipulator and Instrument Control (“Hand”)

The robotic manipulator system controls catheter advancement, rotation, and instrument deployment with precision exceeding manual manipulation. The system supports:

• Automatic optical positioning puncture
• Angiography-guided catheter push
• Interventional channel construction
• Surgical navigation guidance

Key Features

FlashBot is RainMed Medical’s platform vascular interventional robot, integrating proprietary caFFR and caIMR diagnostic modules with robotic catheter manipulation across the full coronary intervention workflow.

• Full-workflow coverage: From diagnostic angiography through treatment and post-procedure evaluation
• Integrated diagnostics: Built-in caFFR and caIMR functional assessment
• Remote operation capability: Potential for telemedicine applications
• Radiation protection: Reduces operator exposure during fluoroscopy
• Procedure standardization: Consistent technique regardless of operator experience level

Technical Capabilities

Based on completed animal experiments, FlashBot has demonstrated:

Animal experiments in Suzhou completed without surgical complications such as vasospasm, verifying the clinical operability, safety, and effectiveness of the system.

Regulatory Status

The system remains in development phase with regulatory submissions pending completion of clinical validation studies.

Clinical Applications

Target procedures:

• Diagnostic coronary angiography
• Percutaneous coronary intervention (PCI)
• Functional assessment during catheterization

Future expansion: RainMed’s roadmap includes extending FlashBot compatibility to cover heart, brain, lung, kidney, and peripheral vascular interventions—addressing the full spectrum of vascular disease with a single platform.

Strategic Context

FlashBot represents the culmination of RainMed’s strategic vision to build a platform-level vascular interventional robot. The company’s commercially successful diagnostic products (caFFR, caIMR) serve as enabling technologies that differentiate FlashBot from competitors focused solely on mechanical catheter manipulation.

The integration of diagnostic AI creates potential for closed-loop surgical workflows where the robot can assess lesions, recommend treatment strategies, execute interventions, and verify outcomes within a single system.

Development Timeline

• 2014: Company founded with vascular interventional robot as core strategic objective
• 2019: Diagnostic modules (caFFR, caIMR) enter development
• 2022: FlashBot system development completed; animal experiments initiated
• 2023: Multiple animal experiments successfully completed
• TBD: Clinical trials and regulatory submissions

Frequently Asked Questions

Is FlashBot currently available for purchase?

FlashBot remains in development phase and is not yet available for commercial purchase. The system has completed animal experiments but awaits regulatory approval.

What makes FlashBot different from other vascular robots?

FlashBot integrates proprietary diagnostic capabilities (caFFR and caIMR) that enable the robot to perform functional assessment during procedures. Most competing vascular robots focus on mechanical catheter manipulation without integrated diagnostic intelligence.

When will FlashBot receive regulatory approval?

RainMed originally targeted 2024 for NMPA certification and CE registration. Current timeline is uncertain pending completion of clinical validation studies.